Tight regulatory mechanisms to maintain repression of human Telomerase (hTERT), the sole protein that synthesizes telomeres, is crucial for normal adult somatic cells. In contrast, enhanced telomerase activity and resulting pathological maintenance of telomeres, is widely understood as causal in >90% of human cancers. These implicate underlying mechanisms connecting hTERT regulation and telomeres, possibly through telomeric proteins, that remain unclear. In light of of recent work by us and others showing non-telomeric function of the telomere-binding protein TRF2, here we examined whether and how TRF2 affected hTERT regulation. Direct binding of TRF2spanning ~450 bp of the hTERT promoter from the Transcriptional Start Site (TSS)led to TRF2-dependent recruitment of the polycomb repressor complex PRC2 in both normal and cancer cells. This induced repressor histone modifications resulting in TRF2-dependent hTERT repression.
Next, we checked whether TRF2 altered transcription of hTERT. Promoter activity (from +33 to -1267 bp hTERT promoter introduced upstream of Gaussia luciferase reporter construct) was markedly enhancedupon siRNA-mediated TRF2 silencing in all the four cell types ( Figure 1B) .
Consistent with this, endogenous hTERT expression was upregulated in both normal and cancer cells on TRF2 silencing; expression of both, the functional reverse transcriptase domain (exon 7/8) as well as the full-length hTERT transcript (exon 15/16) was enhanced (Figure 1 C) . For further confirmation, we tested the effect of TRF2 on intracellular telomerase activity. Silencing of TRF2 resulted in enhanced telomerase activity in all the four cell lines ( Figure 1D) ; and, increase in telomerase protein on TRF2 silencing was also evident (Supplementary Figure 1B) .
Next, we performed immunofluorescence (IF) experiments to check hTERT protein levels within single cells in HT1080 and primary MRC5 cells. On TRF2 silencing two-three fold enhanced hTERT levels was evident in both cell types ( Figure 1E ). In HT1080 cancer cells, enhanced telomerase was found mostly within the nuclei as expected; however, in case of the primary MRC5 cells this was observed outside of the nuclei also, as noted earlier 23, 24 .
For further validation flow-cytometry analysis (fluorescence-assisted cell sorting (FACS)) of hTERT levels following silencing of TRF2 (using TRF2 siRNA as above) in HT1080 cells was done. The mean fluorescence intensity (MFI) of TRF2 decreased by ~16 folds, whereas the hTERT-MFI increased by ~5.2 fold, in cells where TRF2 was silenced relative to untreated control cells ( Figure   1F ). The cell populations monitored were: control (89.1% of 55893) and TRF2-silenced (96.4% of 45716) where staining of TRF2-high: hTERT-low and TRF2-low: hTERT-high cells, respectively, was clear ( Figure 1F ).
In addition to this, we performed rescue experiments using TRF2 siRNA. TRF2 was first depleted in HT1080 cells using siRNA, which gave enhanced hTERT expression. Thereafter, cells were maintained for 72 hrs with no further siRNA addition when TRF2 levels gradually increasedconcomitant decline in hTERT was clearly evident ( Figure 1G ). Taken together, these suggested transcriptional control of functional telomerase by TRF2. The antibody used here for hTERT was confirmed by FACS in super-telomerase cells that constitutively over-express telomerase (characterized earlier 25 ) (Supplementary Figure 1C ).
DNA binding by TRF2 is necessary for transcription regulation of hTERT
We next asked if direct DNA binding by TRF2 is necessary for TRF2-mediated repression of hTERT. To test this, we over-expressed Flag-tagged TRF2-DelM (lacking C-terminal Myb (M) domain), TRF2-DelB (lacking N-terminal Basic (B) domain) or TRF2-DelB-DelM (lacking both B and M domains domains) mutants of TRF2 that lack DNA binding. In all the three mutants we observed enhanced expression of endogenous hTERT full transcript in HT1080, HCT116 and MRC5 primary and HEK293T cells ( Figure 1H ). In addition, over-expression of TRF2-DelM, TRF2-DelB and TRF2-DelB-DelM also resulted in enhanced promoter luciferase activity of hTERT ( Figure 1I ) and increase in telomerase activity in all the four cell lines ( Figure 1J ). As expected, binding of the TRF2-DelB-DelM mutant on the hTERT promoter was not significant (Supplementary Figure 1D ). We also checked, whether the dominant negative effect of TRF2-DelM noted earlier 12 which was likely to reduce the binding of endogenous full-length TRF2 was observed in case of the hTERT promoter.
As expected TRF2 occupancy was lost at the hTERT promoter on over-expression of TRF2-DelB-DelM (Supplementary, Figure 1D ).
Epigenetic state of chromatin at the hTERT promoter is TRF2-dependent
TRF2-mediated change in promoter histone methylation at several promoters spread across the genome was observed earlier 13, [26] [27] [28] [29] [30] Here, we sought to understand whether TRF2-mediated transcriptional repression of hTERT involved altered epigenetic state at the promoter. Changes in two histone-activation (mono and tri-methylated histone H3 lysine 4 (H3K4me1 and H3K4me3)) and two repressors (tri-methylated histone H3 lysine 9 and lysine 27 (H3K27me3 and H3K9me3)) marks were checked at the hTERT promoter following TRF2 silencing. ChIP-PCR for each of the four histone marks using primers spanning a region up to 750 bp upstream of hTERT TSS (as in Figure   1A ) was performed. Interestingly, we found significant loss in only the H3K27me3 repressor mark in both HT1080 and MRC5 primary cells (Figure 2A and B) whereas activation marks H3K4me1, H3K4me3 or the repressor mark H3K9me3 did not change significantly on TRF2 silencing ( Supplementary Figure 2 A and B) .
TRF2-mediated recruitment of the polycomb repressor complex PRC2 at the hTERT promoter
The polycomb-repressor complex 2 (PRC2) is known to catalyse H3K27me3 modification exclusively resulting in gene inactivation [31] [32] [33] . Therefore, we tested if the occupancy of the PRC2 complex on the hTERT promoter was TRF2-dependent. In both HT1080 and MRC5 cells we found that TRF2 silencing resulted in loss of EZH2 (catalytic component of the PRC2 complex) occupancy ( Figure 2C and D) . However, on silencing of EZH2, TRF2 occupancy remained relatively un-altered (Supplementary Figure 2C) suggesting TRF2-dependent recruitment of EZH2/PRC2 complex at the hTERT promoter.
Recruitment of the PRC2 complex through the RE1-silencing factor (REST) throughout the genome was observed earlier [34] [35] [36] . On the other hand, interaction of TRF2 with REST was observed by us and others 12, 26, [37] [38] [39] . We sought to check, therefore, if TRF2 recruited REST on the hTERT promoter.
In both HT1080 and MRC5 cells, TRF2 silencing resulted in loss of REST association from the hTERT promoter region (up to 750 bp upstream) suggesting TRF2-dependent REST occupancy ( Figure 2E , F). This is supported by intracellular interaction of TRF2 and REST noted by us in HT1080 cells earlier 30 and in MRC5 primary cells shown here through co-immunoprecipitation (co-IP) of REST using anti-TRF2 antibody (Supplementary Figure 2D ).
To further substantiate TRF2-dependent REST binding on the hTERT promoter we performed re-ChIP experiments: REST-reChIP from the TRF2 ChIP fraction (see methods) in both HT1080 and MRC5 cells showed TRF2-dependent REST occupancy. We used the CTCF promoter as a negative control for TRF2 ChIP and the synapsin promoter (reported for REST occupancy 40, 41 , but not TRF2) as a positive control for the REST ChIP ( Figure 2G and 2H). As expected, the REST reChIP was negative for synapsin.
Conversely, TRF2-reChIP from the fraction immunoprecipitated using the anti-REST antibody confirmed TRF2 binding (Supplementary Figure 2E ). ReChIP for TRF2 was negative for the synapsin promoter as expected. Together these confirmed TRF2-REST co-occupancy at the hTERT promoter. While silencing of TRF2 resulted in loss of REST occupancy ( Figure 2E , F), REST silencing did not result in loss of TRF2 from the hTERT promoter (Supplementary Figure 2F) supporting TRF2-dependent REST recruitment. Together, these show that TRF2 binding at the hTERT promoter engages the PRC2-REST repressor complex, which results in H3K27me3 modification and induces a restrictive chromatin state that suppresses hTERT expression.
While co-IP of TRF2 with REST was clear ( Supplementary Figure 2E ), co-IP of EZH2 with TRF2 was not evident (Supplementary Figure 2G ). As expected from earlier work we confirmed co-IP of REST with EZH2 (Supplementary Figure 2H ). It is possible, therefore, that TRF2 recruits REST and EZH2 association is through REST.
TRF2 binding on the hTERT promoter can be independent of telomere looping
Interaction of the chromosome 5p telomere end to the relatively close hTERT locus (~1.2 Mb away) through chromatin looping was shown earlier 42 . Authors noted localization of TRF2 at the hTERT promoter and described it to result from physical association with telomeres. Here we sought to test more directly whether TRF2 occupancy at the hTERT was dependent on interaction with telomeres.
For this ,we made a reporter construct by introducing the endogenous hTERT promoter (up to -1300 bp) upstream of the Gaussia luciferase gene. This construct was then inserted at the CCR5 safeharbour locus ~40 Mb away from the nearest telomere using Cas9-mediated genome editing in HEK293T cells (see Methods). Expression of Gaussia luciferase from the inserted construct was enhanced on silencing TRF2 and over expression of TRF2 DNA binding mutants ( Figure 3A) ; as observed for the endogenous hTERT promoter. Next, we tested TRF2 occupancy on the hTERT promoter at the CCR5 locus using specific ChIP-qPCR primers designed for the inserted loci (which spanned from 113 bp upstream of TSS till 196 bp downstream; Figure 3A ). TRF2 occupancy was clearly evident consistent with our observations made earlier with the endogenous hTERT promoter ( Figure 3B ). Together, these support TRF2-mediated transcriptional repression of hTERT.
Following this we reasoned that looping/interaction with telomere ends was likely to result in presence of other telomere binding shelterin factors like POT1, TRF1 and RAP1, along with TRF2, on the inserted promoter. To test this, we selected the interstitial telomeric-like sequence (ITS) ~100
Kb downstream of hTERT exon reported to engage telomeres through looping of the 5p chromosome (Kim et al., 2016) as positive control 43 . The GAPDH promoter was used as negative control. In contrast to TRF2 none of the other factors tested (POT1, TRF1, RAP1) showed significant occupancy at the exogenously inserted 1300 bp hTERT promoter ( Figure 3D ); whereas their occupancy was observed at the Chromosome 5p ITS sequence. Telomeric binding of POT1, TRF1, RAP1 and TRF2 was confirmed independently in each case using telomere-specific probe (Supplementary Figure 3A ).
Next, we checked if TRF2 occupancy at the endogenous hTERT promoter was due to looping.
Using the same argument as above we tested occupancy of other shelterin factors POT1, TRF1 and RAP1, which would be likely if telomeres physically associated with the hTERT promoter. Here also while TRF2 occupancy was clear ( Figure 1A ), we did not find occupancy of POT1, TRF1 or RAP1 in the region up to 750 bp upstream of the endogenous hTERT promoter in HT1080 cells ( Figure 3E ); whereas occupancy on the chromosome 5p ITS was as expected. Telomeric binding of the shelterin proteins was confirmed independently using telomere-specific qPCR probes following ChIP (Supplementary Figure 3B ). Together, our results show occupancy of TRF2 at the hTERT promoter was independent of telomeric association and likely to be in addition to telomeredependent effects noted earlier depending on the length of the 5p telomere.
TRF2 binding on the hTERT promoter is dependent on DNA secondary structure Gquadruplex
Because the hTERT promoter had multiple G-quadruplexes [18] [19] [20] [21] (shown in Supplementary Figure   4A ) we analyzed the TERT promoter across vertebrates. And, noted with interest that several vertebrate species have one or more G-quadruplexes within 500 bp of TERT TSS ( Figure 4A ).
Previous work by us and others has reported interaction of TRF2 with G-quadruplexes from promoters as well as telomere ends 12, 44, 45 .Therefore, we next asked if G-quadruplexes in the hTERT promoter interacted with TRF2.
First, we tested, G-quadruplex-TRF2 association at the hTERT promoter, we focused on two Gquadruplexes (Supplementary Figure 4A and B). Formation of G-quadruplex in solution for both the motifs was reported earlier 21, 47 . Two mutations (at -124 bp (G>A) and -146 bp (G>A) from TSS) (Supplementary Figure 4A ) were found to be frequently associated with several cancers including glioblastoma (GBM) and melanomas 22, [48] [49] [50] . Furthermore, both the mutations substantially destabilized the respective G-quadruplexes in solution 21 , which was further confirmed by us (Supplementary Figure 4B ). To begin with, we checked TRF2 binding to the wildtype hTERT promoter G-quadruplexes in comparison to their respective mutants. For this, flag-tagged TRF2 was expressed in HT1080 cells. Lysate from these cells was incubated with biotinylated wild type or mutant (-124G>A or -146G>A) oligonucleotides and pulled down using streptavidin beads (Methods). Using anti-flag-antibody we observed TRF2 had enhanced interaction with wildtype relative to mutant oligonucleotides in both cases ( Figure 4B ). In addition, ELISA with recombinant TRF2 showed about four-fold higher affinity for hTERT promoter G-quadruplexes relative to the respective mutant oligonucleotides that destabilized G-quadruplex formation in both cases ( Figure   4C , D).
Next, we used the hTERT promoter-gaussia luciferase reporter inserted at the CCR5 locus, where G>A substitutions were introduced either at the -124 or the -146 th positions from TSS ( Figure 4E ). TRF2 occupancy at the inserted hTERT promoter was significantly depleted in case of both the substitutions compared to the unsubstituted case ( Figure 4E ). As expected, TRF2 occupancy on the endogenous hTERT promoter remained unaltered in these cells (Supplementary Figure 4C ). Taken together results suggest that for TRF2 binding at the hTERT promoter the two tandem Gquadruplexes tested are intact.
To further check this, intracellular presence of the hTERT promoter G-quadruplexes we performed ChIP using the G-quadruplex-binding antibody BG4 46 . However, we were not able to detect BG4 occupancy on the hTERT promoter ( Figure 4F ). We reasoned, as also mentioned by authors 46 , that this could be due to the presence of TRF2 on the hTERT promoter, which might restrict binding of BG4. Therefore, we checked for BG4 occupancy after silencing TRF2. In cells lacking TRF2 we found significant occupancy of BG4 on the hTERT promoter ( Figure 4F ). Together these support the presence of G-quadruplexes in the hTERT promoter, and that the G-quadruplexes might associate with TRF2 inside cells.
TRF2 occupancy is lost in cancers with hTERT promoter mutations
Following the above-stated results, we tested if hTERT promoter G>A mutations at the -124 or the -146 th bp position from TSS, frequently reported to be associated with human GBM, melanoma and other cancers 22, [48] [49] [50] , affected TRF2 binding. We first tested two GBM, U87MG and LN229, transformed cell lines with activated telomerase that had the -124G>A mutation in both cases 51, 52 . In both cell types we could not detect any TRF2 occupancy at the hTERT promoter ( Figure 4G , H).
Further, TRF2 over expression also did not result in TRF2 binding at the hTERT promoter in both U87MG and LN229 cells (Supplementary Figure 4D ).
Further, for the -146G>A hTERT promoter mutation ,we tested three transformed cancer cell lines pairs with or without the mutation (gift from Tergaonkar Lab). In HCT116 colorectal carcinoma cells the -146G>A mutation was introduced resulting in telomerase hyperactivation 53 . The second and third cancer cell line pairs constituted BLM6 melanoma and T98G GBM cells where the -146G>A mutation occurred intrinsically. This was corrected by making A>G substitution in both cell lines, which gave telomerase repression as expected and reported earlier 53 .
In all the three cases, TRF2 occupancy was significantly lost from the hTERT promoter in case of the -146G>A mutation relative to the corresponding cell line without the mutation (Figure 4 I, J, K).
We earlier noted loss/gain of H3K27me3 to be TRF2-dependent (Figure 2A, B ). Here we checked this taking HCT116 cells as a candidate caseloss of H327me3 from the hTERT promoter in cells with the mutation (as expected from loss of TRF2) was clearly observed relative to the HCT cells that had no mutation, along with gain in H3K4me3 as reported earlier by Akincilar et al. 53 (Supplementary Figure 4D ).
For further confirmation, we studied primary cells from grade-four GBM patients. Upon sequencing the hTERT near promoter (38bp downstream to 237bp upstream of ATG) we found two cases with -124G>A mutation (G7, G166); one with -146G>A mutation (G14); and one case with no mutation (G144). Telomerase activity, as expected, was several-folds higher in GBM cells with either -124/-146 G>A mutation (G7, G166 or G14) compared to G144, which had no mutation in the hTERT These show that in multiple transformed and primary patient-derived GBM/melanoma cells, TRF2 occupancy was substantially reduced in case of G>A mutations in the hTERT promoter. Taken along with other findings, this suggest that telomerase hyperactivation, frequently found in cancers with -124/-146 mutations in the hTERT promoter, causally associated with high grade GBM, melanoma and other cancers 22,48-50 might be due to loss of TRF2-mediated repression of hTERT.
Stabilization of G-quadruplex using ligands reinstatesTRF2 binding and repressor chromatin
We tested four reported intracellular G-quadruplex binding ligands [54] [55] [56] [57] in LN229 cells (-124G>A mutation in the hTERT promoter) (Supplementary Figure 5A , 5B Supplementary Table 1 ). Two ligands, SMH1-4.6 and JD83 showed relatively more effect on hTERT repression. In U87MG cells treatment with SMH1-4.6 or JD83 resulted in ~40-50% repression of hTERT ( Figure 5A ). TRF2 expression remained relatively unaltered in presence of the ligands in both the cell lines (Supplementary Figure 5B ). SMH1-4.6 and JD83 also suppressed telomerase activity in both U87MG and LN229 cells ( Figure 5B ).
Next, we asked whether and how treatment with the G-quadruplex-binding ligands affected TRF2 occupancy on the hTERT promoter. In case of both SMH1-4.6 and JD83, there was significant increase in TRF2 occupancy at the hTERT promoter in LN229 and U87MG cells ( Figure 5C , D).
Based on our results showing TRF2-mediated gain in H3K27me3 modification (Figure 2A , B), we next checked and found significant increase in the H3K27me3 histone repressor mark at the hTERT promoter in both LN229 and U87MG in presence of SMH1-4.6 and JD83 ( Figure 5E , F). To further ascertain the effect of G-quadruplex binding ligands on TRF2 occupancy we used the hTERT promoter gaussia reporter (with or without -124/-146 mutation) inserted at the CCR5 locus.
Treatment with SMH1-4.6 resulted in significant increase in TRF2 occupancy on the inserted hTERT promoter ( Figure 5G ). Taken together, this suggests ligand-mediated G-quadruplex stabilization results in recovery of TRF2 occupancy, gain in histone repressor H3K27me3 and consequent telomerase suppression in cells with hTERT promoter mutations that disrupt G-quadruplex formation.
Discussion
Taken together, our results support TRF2-dependent recruitment of the PRC2-REST repressor complex maintains a non-permissive state of chromatin at the hTERT promoter through repressor histone modifications. This results in TRF2-mediated repression of hTERT expression. Experiments using recombinant TRF2 and TRF2-mutants devoid of DNA binding support transcriptional repression through direct DNA binding by TRF2 at the hTERT promoter. In addition, cell lines with hTERT promoter mutations (using CRISPR-Cas-mediated single-base editing) and an exogenous reporter cassette with specific base substitutions which disrupt the TRF2 binding site, where TRF2-mediated hTERT repression was lost, further confirmed transcriptional role of TRF2 in hTERT regulation.
TRF2 binding on the hTERT promoter was dependent on the presence of promoter G-quadruplex.
Multiple lines of evidence reported herein support this. First, recombinant TRF2 binds with nanomolar affinity to G-quadruplexes from the hTERT promoter in solution, which was significantly lower when single-base substitutions are made, that disrupt the G-quadruplex stability ( Figure 4C , D). Second, association of the antibody BG4, reported widely to be specific for intracellular Gquadruplexes, was found at hTERT promoter only when TRF2 was silenced likely because TRF2 association with the G-quadruplex competes with BG4 suggesting intracellular TRF2-G-quadruplex interaction ( Figure 4F ). Third, base substitutions that disrupt G-quadruplex when incorporated into the exogenously inserted promoter-reporter resulted in significantly decreased TRF2 occupancy, relative to the un-substituted promoter ( Figure 4E ). Fourth, in mutant cell lines with or without base substitution(s) (identical to the ones in binding assays with recombinant TRF2) that disrupt Gquadruplexes in the hTERT promoter, TRF2 association was significantly lower in case of cells with the G-quadruplex-disrupting substitution(s) (Figure 4 G-M). Further, this is consistent with work by us showing TRF2-G-quadruplex interactions at the p21, PCGF3 promoters and more recently in a study where TRF2-G-quadruplex binding was found to be spread throughout genome 12, 44, 58 . Earlier a truncated version of TRF2 was noted to bind the telomeric G-quadruplex in solution 45 .
Based on this we sought to understand whether hTERT promoter mutations frequently found in aggressive GBM and melanoma that result in hTERT activation 22,48-50reported to destabilize Gquadruplexes 21 might disrupt interaction of TRF2 with the hTERT promoter. Using cancer cell lines as well as glioblastoma patient-derived primary cells harbouring G-quadruplex-disrupting hTERT promoter mutations we tested this: loss of TRF2 binding in case of cells with hTERT promoter mutation(s), but not otherwise, along with decrease in repressor histone modification (H3K27me3) and enhanced hTERT expression was clear in all the cases. We further tested the possibility that intracellular G-quadruplex-binding ligands might stabilize the promoter G-quadruplex (in cells with promoter mutations) and thereby reinstate TRF2 binding at the hTERT promoter. In presence of two different types of G-quadruplex ligands, TRF2 binding and repressor chromatin at the hTERT promoter, and hTERT repression was regained, in support of the TRF2-G-quadruplex-dependent mechanism.
Although direct transcriptional repression of hTERT by TRF2 has not been reported earlier, high TRF2 along with low hTERT levels was observed in CD4 T lymphocytes and a osteosarcoma- Promoter mutation(s) in hTERT, on the other hand, was also reported to either generate site(s) that resulted in binding of transcription factors GABPA/B1 33,63,64 and ETS1 65 , or RAS-ERK-mediated inhibition of HDAC1 association 66 , leading to telomerase activation in GBM, hepatocellular carcinoma and melanoma cells. GABPA along with the histone acetyl transferase BRD4 was also noted to bind the hTERT promoter with mutation(s) inducing permissive chromatin state 53 . Together, with the presence of tandem G-quadruplexes in the hTERT near promoter, the likelihood of Gquadruplex-dependent mechanisms of transcription factor association resulting in permissive/restrictive chromatin conformation has been discussed by several groups 42, 43, 67, 68 .
Consistent with this, stabilization of G-quadruplexes was noted to mask binding of the well-studied regulatory factors Sp1 and CTCF at the hTERT promoter 18, 68, 69 . From our results here, it is likely that 42 . Our results, on the other hand, support direct binding of TRF2 to the hTERT promoter that is independent of telomeres (or through non-telomeric TRF2) from multiple lines of evidence.
First, we reasoned that telomere-association would result in presence of other telomeric factors like TRF1, RAP1 and POT1 at the hTERT promoter along with TRF2this was not the case ( Figure   5D ). Second, considering the likelihood of telomere looping to diminish with physical distance we inserted an exogenous hTERT promoter-reporter ~46 Mb away from the nearest telomere endhere also TRF2 association was clear whereas other telomere-bound factors were absent ( Figure   5B , C). Overall this is consistent with earlier work showing non-telomeric TRF2 binding throughout the genome 12, 26 . Therefore, interestingly, it is likely that both telomere-dependent 42 and telomereindependent mechanisms of TRF2 interaction regulate hTERT. Further work will be required to determine in what contexts these mechanisms work, particularly in cases of ageing when telomere length changes.
In conclusion, evidence supporting TRF2-mediated re-suppression of hTERT using small molecule ligands in aggressive GBM and other cancers, where telomerase is hyperactivated due to hTERT promoter mutations, has important therapeutic potential. Perhaps more importantly, results demonstrate mechanisms of how hTERT is maintained in a repressed state by TRF2 in normal cells; and, that deregulation of the repression in many cases induce telomerase reactivation in cancer cells. Together, these implicate molecular connections between telomeres and telomerase, through telomeric factors like TRF2, which might be important in how normal and cancer cells manage telomeres through (de)activation of telomerase in humans. 
Materials and Methods

Cell lines, media and culture conditions
CRISPR Mediated Insertion of TERT promoter driven Gaussia Luciferase into CCR5 locus.
The TERT promoter driven Gaussia Luciferase insert construct was obtained from a Genecopoeia promoter reporter clone (catalogue no-HPRM25711-PG04). The insert sequence was cloned into AY10_pS.
Donor.R5.TS, a gift from Manuel Goncalves (Addgene plasmid # 100292); the donor vector sequence after cloning has been provided in supplementary information. The TERT promoter donor vector with mutation at -124 position was generated using Quikchange SDM kit (Agilant) according to the manufacturers' protocol. For cleavage at CCR5 locus a reported gRNA sequence (5'-GGAGAGCTTGGCTCTGTTGGGGG-3')1 was cloned into the pX459 v2.0, a gift from Feng Zhang, that co-expresses cas9 protein and the gRNA. The gRNA cloned pX459 and the donor vector were co-transfected using FUGENE HD transfection agent according to the manufacturers' protocol. Starting from 36 hours post transfection, the cells were treated with 2ug/ml puromycin for 3 days for selecting cells that have taken up pX459 plasmid. After growing for 5 days after selection, the cells were seeded into 96 well plates after dilution for clonal selection. 40 clones were screened using Gaussia luciferase activity and PCR to find out the positive clones (primers provided in supplementary information). 
Secondary antibodies:
anti-Rabbit-HRP(CST), anti-Mouse-HRP(CST), anti-rabbit Alexa Fluor® 488, anti-mouse Alexa Fluor® 594 (Molecular Probes, Life Technologies).
Analysis of sequence data for detecting conserved PG4 motifs
PG4 motifs were identified from different custom fetched sequences from TERT upstream promoter region from various mammalian clades using Quadbase 2. Sequence homology and conservation scores were determined using neighbour joining cluster generation algorithm in the publicly available multiple sequence alignment tool MUSCLE.
ChIP (Chromatin Immunoprecipitation)
ChIP assays were performed as per protocol previously reported in Mukherjee et al, 2019. ChIP assays were performed using relevant primary antibody. IgG was used for isotype control in all ChIP experiments. Three million cells were harvested and fixed for each were fixed with ~1% formaldehyde for 10 min and lysed.
Chromatin was sheared to an average size of ∼200-300 bp using Biorupter (Diagenode). 10% of sonicated fraction was processed as input using phenol-chloroform and ethanol precipitation. ChIP was performed using 3 μg of the respective antibody incubated overnight at 4°C. Immune complexes were collected using herring sperm DNA-saturated Magnetic Dyna-beads (protein G/A) and washed extensively using a series of low salt, high salt and LiCl Buffers. The Dynabeads were then resuspended in TE(Tris-EDTA pH 8.1) buffer and incubated with proteinase K at 55º C for 1hr .Then, phenol-chloroform-isoamyl alcohol was utilized to extract DNA from the proteinase K treated fraction. DNA was precipitated by centrifugation after incubating overnight at -20 º C with isopropanol with glycogen and 3M sodium acetate. The precipitated pellet was washes with freshly prepared 70% ethanol and resuspended in nuclease free water. ChIP DNA was further validated by qRT-PCR method.
The primer sequences for ChIP-qPCR on TERT promoter is as follows: 
Primer name Sequence
Re-ChIP:
For Re-ChIP of TRF2 immunoprecipitated fraction with REST, the above stated ChIP protocol was followed with a starting harvest of 6 million cells with pull-down of TRF2 mouse monoclonal antibody using protein G dynabeads. For Re-ChIP, half the pull-down fraction was resuspended in TE buffer with 10mM DTT after the salt buffer washes and incubated for 30 mins at RT. Following this the fraction was centrifuged at 10K rpm at 4º C for 10 mins and supernatant was used as lysate for REST ChIP using REST rabbit monoclonal antibody and pull down using protein A Dynabeads.
Immunoprecipitation of proteins
Six million cells were collected and washed in cold 1X PBS and lysed using RIPA (sigma) with 1x mammalian Protease inhibitor Cocktail as per manufacturer protocol. For immunoprecipitation experiments 1 mg of protein was incubated for 4 hours at 4°C with primary antibody in ratio recommended by manufacturer for immunoprecipitation. The pull-down was performed using Catch and Release co-immunoprecipitation kit (Millipore) as per manufacturer's protocol.
Immunofluorescence microscopy
Adherent cells were seeded on coverslips and allowed to reach a confluency of ~ 70%. Cells were fixed using freshly prepared 4% Paraformaldehyde by incubating for 10 min at RT. Cells were permeabilised with 0.5% Triton™ X-100 (10 min at RT) and treated with blocking solution (5% BSA in PBS) for 2 hrs at RT. All the 
Immuno-Flow cytometry:
3 million cells for each condition were fixed using 4% formaldehyde for 10 mins at RT followed by 3 ice cold PBS washes for 5 mins each. Cells were permeabilised using 90% Methanol (pre-chilled) for 5 mins and followed by three ice cold PBS washes for 5 mins each. Dilution of primary antibodies were made (TERT rabbit and TRF2 mouse) in 1% BSA ( in PBS) in 1:250 ratio by volume. Cells were incubated with primary antibody cocktail for 2 hrs at RT. Three ice cold PBS washes to cells (10 mins each) were given and secondary antibodies-rabbit Alexa Fluor® 488(1:1000) / mouse Alexa Fluor® 594(1:1000) in 1% BSA (in PBS) were added. Cells were incubated at RT for 1hr and given three ice cold PBS washes (10 mins each).
Cells were resuspended in 0.5 ml of PBS and scored for Fluorescence intensity in an Acuuri c6 flow cytometer in the FL1 (488 nm) and FL3 (594 nm) channels. The FCS files were analyzed using Flow-Jo (version 10) software.
Transfections:
Cells were transfected using protocols previously described for TRF2 WT and mutant mammalian expression plasmids and TRF2 siRNA pool was used for TRF2 silencing 5'GGC-UGG-AGU-GCA-GAA-AUA-U3', 5'CUG-GGC-UGC-CAU-UUC-UAA-A3', 5'GCU-GCU-GUC-AUU-AUU-UGU-A3' as described in Mukherjee et al,
2019.
Gaussia-Luciferase assay
Minimal promoter region of TERT (~1300 bp starting from 48 bp downstream of Transcription start site) procured from Genecopoeia-HPRM25711-PG04 (pEZX-PG04.1 vector) .Gaussia luciferase kit from Promega was used for detecting secreted Gaussia luciferase signal as per manufacturer's protocol.
Real time PCR for mRNA expression:
Total RNA was isolated using TRIzol® Reagent (Invitrogen, Life Technologies) according to manufacturer's instructions. RNA was quantified and used for cDNA preparation using Applied Biosciences kit. 
Western blotting
For western blot analysis, protein lysates were prepared by resuspending cell pellets in passive lysis buffer/RIPA with 1x mammalian Protease inhibitor Cocktail. Protein was separated using 10% SDS-PAGE and transferred to polyvinylidene difluoride membranes (Immobilon FL, Millipore). After blocking the membrane was incubated with primary antibodies-anti-TRF2 antibody (Novus Biological), anti-TERT antibody (Abcam), anti-REST(Millipore), anti-EZH2(CST) and anti-GAPDH antibody (Santa-cruz). Secondary antibodies, anti-mouse and anti-rabbit HRP conjugates were from CST. The blot was finally developed by using Millipore HRP chemiluminescene detection kit and images in a GE chemiluminiscence imager.
Circular dichroism
The circular dichroism (CD) spectra were recorded on a Jasco-810 Spectropolarimeter equipped with a Peltier GraphPad Prism7 was used for analysis.
Telomerase activity: One million cells were lysed using CHAPS lysis buffer and 1ug concentration normalized protein dilutions were used for detecting telomerase activity using ROCHE TeloTAGGG™ Telomerase PCR ELISA kit.
Oligo-pulldown assay:
Total cell lysate of >2000ug concentration was isolated using RIPA buffer (without SDS) with 1X mPIC. Lysate was pre-cleared for cellular biotin (if any) by adding 60ul of Dynabeads MyOne Streptavidin C1 (cat no65001) beads per sample and rotating on a 4-degree celsius for 2 hours. Streptavidin beads were then removed using a magnetic stand and the lysate was divided into two equal parts. To one the wild type biotinylated oligo was added, while to the other mutant oligo was added, both amounting to 50pmoles. The lysate was incubated on rotor with oligos for 16hrs at 4-degree Celsius. Thereafter the protein and DNA were crosslinked for 15min in UV crosslinker. Thereafter 100ul of Streptavidin beads were added to each tube post twice washing of beads in 1XPBST. Beads were incubated with cross-liked lysate for 2 hours. Post this, beads were separated on magnetic stand and washed twice in 1X wash buffer (20mM Tris+10mM NaCl+ Tween 0.1%).
Lastly the bound protein was eluted using Elution buffer (1MTris HCl pH6.8+10% SDS+ Bitoin 25mM). The beads were re-suspended in 50ul of elution buffer and heated at 95 degree Celsius for 5 min, the buffer was then stored in fresh tube, the process was repeated with 50ul of elution buffer. Of this total eluted protein, 60ul
was run on SDS PAGE gel after adding 6X protein loading dye, as in a normal western blot protocol. 
